DOCSLIB.ORG

Poor Mobilization Is an Independent Prognostic Factor in Patients with Malignant Lymphomas Treated by Peripheral Blood Stem Cell Transplantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poor Mobilization Is an Independent Prognostic Factor in Patients with Malignant Lymphomas Treated by Peripheral Blood Stem Cell Transplantation Bone Marrow Transplantation (2006) 37, 719–724 & 2006 Nature Publishing Group All rights reserved 0268-3369/06 $30.00 www.nature.com/bmt ORIGINAL ARTICLE Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation V Pavone1,2, F Gaudio1, G Console3, U Vitolo4, P Iacopino3, A Guarini1, V Liso1, T Perrone1 and A Liso5 1Hematology Department, University of Bari, Bari, Italy; 2Hematology Department, Hospital ‘C Panico’, Tricase, Italy; 3Bone Marrow Transplantation Unit, Reggio Calabria, Italy; 4Haematology Department, Turin Hospital, Turin, Italy and 5Hematology Unit, University of Foggia, Foggia, Italy Haemopoietic stem cell therapy is an increasingly adopted ment frequently employed in relapsed malignant lympho- procedure in the treatment of patients with malignant mas (ML) or in very high-risk ML.2–12 The presence of lymphoma. In this retrospective analysis, we evaluated HSCs in peripheral blood is usually extremely low before 262 patients, 57 (22%) with Hodgkin’s and 205 (78%) mobilizing procedures, and engraftment of CD34 þ per- with non-Hodgkin’s lymphomas (NHL), and 665 harvest- ipheral blood stem cells (PBSC) depends on the infusion of ing procedures in order to assess the impact of poor an adequate number of CD34 þ stem cells to restore mobilization on survival and to determine the factors that haemopoiesis.13–23 Indeed, the number of CD34 þ cells is may be predictive of CD34 þ poor mobilization. The commonly used to predict the potential engraftment of mobilization chemotherapy regimens consisted of high- harvested HSC.17,19,22,23 A cutoff of 20CD34 þ cells/mlin dose cyclophosphamide in 92 patients (35.1%) and a high- the peripheral blood has been arbitrarily defined to predict dose cytarabine-containing regimen (DHAP in 87 patients a successful collection procedure, and an infusion of a –(33.2%), MAD in 83 (31.7%)). The incidence of minimum of 2.5 Â 106 CD34 þ cells/kg to achieve a safe poor mobilizers (o2 Â 106 CD34 þ cells/kg) was 17.9% engraftment.20,21 A good mobilization is mainly achieved overall, with a 10% of very poor mobilizers (p1 Â 106/ by combining chemotherapy and haemopoietic growth kg). Refractory disease status and chemotherapeutic load factors (HGF). (43 regimens) before mobilization played a negative role The use of different chemotherapy schedules and and were associated with poor mobilization. Survival various HGF (G-CSF, GM-CSF, stem cell factors, IL-3, analysis of all harvested patients showed an overall etc) to perform HSC collecting procedure has been survival at 3 years of 71% in good mobilizers vs 33% in reported.13–15,24 However, for patients treated with any poor mobilizers (P ¼ 0.002). The event-free survival at given chemotherapy regimen, the time to optimal number 3 years was 23% in poor mobilizers and 58% in good of CD34 þ cells in peripheral blood varies greatly and mobilizers (P ¼ 0.04). We conclude that in NHL patients, different variables need to be considered in order to obtain poor mobilization status is predictive of survival. a reliable prediction of good mobilization.25–29 A total of Bone Marrow Transplantation (2006) 37, 719–724. 10–12% of patients with ML do not reach the minimum doi:10.1038/sj.bmt.1705298; published online 6 March threshold of 2 Â 106 CD34 þ collected cells/kg and are 2006 considered poor mobilizers.29–32 Data in the literature on Keywords: malignant lymphoma; mobilizing regimens; poor mobilizers suggest an influence of disease status, bone stem cells; CD34 þ cells marrow involvement, number of chemotherapies and of the different kinds of mobilizing regimen, but a reproducible model predictive of poor mobilization is still lacking.25–32 In our retrospective study of 262 consecutive patients with Introduction ML, we analysed the impact on survival of poor mobiliza- tion expressed as overall survival (OS) and event-free Haemopoietic stem cell (HSC) transplantation has been survival (EFS). We also analysed the role of several widely performed to support high-dose chemotherapy in 1–7 haematological and clinical variables in the harvest of haematological malignancies. In lymphoid malignancies, CD34 HSC. autologous stem cell transplantation (ASCT) is the treat- Patients and methods Correspondence: Dr V Pavone, Hematology Department, University of Beri, Via LRicchioni 16, 70124 Bari, Italy. E-mail: [email protected] Patients characteristics Received 1 April 2005; revised 19 December 2005; accepted 20 December From January 1998 to October 2002, a total of 665 2005; published online 6 March 2006 harvesting procedures were performed in 262 patients (120 Poor mobilization in malignant lymphomas V Pavone et al 720 male and 142 female patients, mean age 45 years, range 16– Table 1 Patients’ characteristics and association with poor 63) in the participating centres: the Bone Marrow mobilization Transplantation Unit of Reggio Calabria, the Haemato- Total Good Poor P logy Department of Turin Hospital and the Haematology patients mobilizer mobilizer Department of Bari. According to the REAL/WHO 262 215 47 classification, there were 62 (23.7%) patients with follicular Median age at mobilization 45 43 55 lymphomas, 143 (54.6%) with diffuse large cell lymphomas Sex (M/F) 120/142 99/117 21/25 (DLCL) and 57 (21.8%) with Hodgkin’s lymphomas (HL); stage III–IV disease was present in 197 patients (75.2%) Histology and 175 patients (66.8%) had bone marrow involvement. Grade I follicular NHL 62 44 18 Systemic B symptoms were present in 161 patients (61.5%). DLCL 143 122 21 Hodgkin’s lymphoma 57 507 An age-adjusted international prognostic index (IPI) score X2 was documented in 115 patients (43.9%). At the time of Clinical and laboratory data at mobilization PBSC mobilization, 209 patients (79.8%) were considered Extranodal sites X2 11094 16 to be responsive to chemotherapeutic treatment: 40patients Performance status 2–4 92 81 11 Bulky disease 172 138 34 (15.3%) were in first complete remission, 169 patients B symptoms 161 124 37 (64.5%) in first partial remission and the remaining 53 Age-adjusted IPI 2,3 115 85 30 patients (20.2%) had relapsed or refractory disease Abnormal LDH 168 125 43 (Table 1). Abnormal 157 128 29 beta2microglobulin Stage III–IV 197 155 42 Mobilizing procedures. The mobilization chemotherapy Bone marrow involvement regimens were cyclophosphamide (CPM) (5 g/m2)in92 At diagnosis 175 132 43 patients (35.1%), DHAP (cisplatin 100 mg/m2 intrave- At mobilization 62 4022 nously (IV) by continuous infusion over 24 h, followed by 2 Previous chemotherapy cytosine arabinoside in two pulses each at a dose of 2 g/m First line given 12 h apart, dexamethasone 40mg IV given on days 1– ABVD 43 35 8 4) in 87 patients (33.2%) and MAD (cytosine arabinoside BEACOPP 14 11 3 in two pulses each at a dose of 2 g/m2 given 12 h apart on CHOP – CHOP like 79 65 14 2 ProMACE/CytaBOM 52 43 9 days 1–4, mitoxantrone 10mg/m on days 3–4, dexametha- Mega-CEOP 41 34 7 sone 40mg IV given on days 1–4) in 83 (31.7%). For all HDS 33 27 6 patients, subcutaneous administration of granulocyte colony stimulating factor (G-CSF) (5 mg/kg, once daily) Second/third line MIME 48 39 9 was commenced on day 2 and continued until completion DHAP 185 152 33 of the PBSC harvest. FC 18 15 3 FND 38 31 7 Stem cell collection. Stem cell collection was performed in IEV 55 45 10 all participating centres with a Fenwal CS 3000 (Baxter, Previous rituximab use 66 57 9 USA). Peripheral blood stem cell harvesting was started Disease status at mobilization when a white blood count (WBC) 41 Â 103/ml and 410 1 CR 4037 3 CD34 þ cells/ml were reached.33 For every bag harvested, 1 PR 169 1609 Relapse 28 12 16 mononuclear cells (MNC)/kg and CD34 þ cells/kg were Refractory 25 2 23 0.008 evaluated at the end of each aphaeresis. Mobilizing regimens Flow cytometry assay for CD34 þ cell estimation. A20ml CPM 92 76 16 DHAP 87 73 14 portion of whole blood was incubated for 30min at 4 1C MAD 83 66 17 with 10 ml of fluorescein isothiocyanate (FITC)-conjugated Median no. of prior treatment 3 2 4 0.02 monoclonal antibody HPCA2. regimens The leucocyte population was analysed by acquiring 75 000 events, using a Becton Dickinson FACScan with a Abbreviations: ABVD ¼ adriamycin, bleomycin, vinblastine, dacarbazine; BEACOPP ¼ bleomycin, etoposide, doxorubicin, cyclophosphamide, vin- 2 W argon ion laser as a light source. Excitation was cristine, procarbazine, prednisone; CHOP ¼ cyclophosphamide, doxorubi- allowed at 488 nm and fluorescence was measured at cin, vincristine, prednisone; CPM ¼ cyclophosphamide; CR ¼ complete 530nm. remission; DHAP ¼ dexamethasone, high-dose cytarabine, cisplatinum; DLCL ¼ diffuse large cell lymphoma; FC ¼ fludarabine, cyclophos- phamide; FND ¼ fludarabine, mitoxantrone, dexamethasone; HDS ¼ Statistical analysis high-dose sequential chemotherapy; IEV ¼ ifosfamide, epirubicin and We analysed the following variables: age, gender, histology, etoposide; IPI ¼ international prognostic index; MAD ¼ mitoxantrone, clinical and laboratory data at mobilization (extranodal high-dose cytarabine, dexamethasone; MEGA-CEOP ¼ cyclophosphamide, epirubicin, vincristine, prednisone; MIME ¼ mitoxantrone, ifosfamide, site performance status, bulky disease, B symptoms, age- methotrexate, etoposide; NHL ¼ non-Hodgkin’s lymphoma; PR ¼ partial adjusted IPI, abnormal lactate dehydrogenase (LDH), remission; ProMACE-CytaBOM: cyclophosphamide, doxorubicin, etopo- abnormal beta2microglobulin, stage, bone marrow involve- side, cytarabine, bleomycin, vincristine, methotrexate prednisone. ment, type of previous chemotherapy, number of previous Bone Marrow Transplantation Poor mobilization in malignant lymphomas V Pavone et al 721 chemotherapy, disease status at mobilization, mobilizing 160 regimens). (94.7%) Patients were divided into good and poor mobilizer groups. Comparisons between groups were performed 37 40 (92.5%) using the test.
Load more

Recommended publications
  • Primary Mediastinal Large B-Cell Lymphoma
    Primary Mediastinal Large B-Cell Lymphoma Page 1 of 13 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. Note: Consider Clinical Trials as treatment options for eligible patients. PATHOLOGIC DIAGNOSIS INITIAL EVALUATION ESSENTIAL: 5 ● Physical exam: attention to node-bearing areas, including Waldeyer's ring, ESSENTIAL: and to size of liver and spleen ● ECOG performance status ● Hematopathology review of all slides with at least one paraffin ● B symptoms (Unexplained fever >38°C during the previous month; block or 15 unstained slides representative of the tumor. Rebiopsy if Recurrent drenching night sweats during the previous month; Weight consult material is nondiagnostic. loss >10 percent of body weight ≤ 6 months of diagnosis) ● Adequate morphology and immunophenotyping to establish 1 ● CBC with differential, LDH, BUN, creatinine, albumin, AST, diagnosis ALT, total bilirubin, alkaline phosphatase, serum calcium, uric acid ○ Paraffin Panel: CD3, CD20 and/or another pan-B-cell marker ● Beta 2 microglobulin (CD19, PAX-5, CD79a) or ● Screening for HIV 1 and 2, hepatitis B and C (HBcAb, HBsAg, HCV
    [Show full text]
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’S Lymphomas Version 2.2015
    NCCN Guidelines Index NHL Table of Contents Discussion NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’s Lymphomas Version 2.2015 NCCN.org Continue Version 2.2015, 03/03/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . Peripheral T-Cell Lymphomas NCCN Guidelines Version 2.2015 NCCN Guidelines Index NHL Table of Contents Peripheral T-Cell Lymphomas Discussion DIAGNOSIS SUBTYPES ESSENTIAL: · Review of all slides with at least one paraffin block representative of the tumor should be done by a hematopathologist with expertise in the diagnosis of PTCL. Rebiopsy if consult material is nondiagnostic. · An FNA alone is not sufficient for the initial diagnosis of peripheral T-cell lymphoma. Subtypes included: · Adequate immunophenotyping to establish diagnosisa,b · Peripheral T-cell lymphoma (PTCL), NOS > IHC panel: CD20, CD3, CD10, BCL6, Ki-67, CD5, CD30, CD2, · Angioimmunoblastic T-cell lymphoma (AITL)d See Workup CD4, CD8, CD7, CD56, CD57 CD21, CD23, EBER-ISH, ALK · Anaplastic large cell lymphoma (ALCL), ALK positive (TCEL-2) or · ALCL, ALK negative > Cell surface marker analysis by flow cytometry: · Enteropathy-associated T-cell lymphoma (EATL) kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20, CD30, CD4, CD8, CD7, CD2; TCRαβ; TCRγ Subtypesnot included: · Primary cutaneous ALCL USEFUL UNDER CERTAIN CIRCUMSTANCES: · All other T-cell lymphomas · Molecular analysis to detect: antigen receptor gene rearrangements; t(2;5) and variants · Additional immunohistochemical studies to establish Extranodal NK/T-cell lymphoma, nasal type (See NKTL-1) lymphoma subtype:βγ F1, TCR-C M1, CD279/PD1, CXCL-13 · Cytogenetics to establish clonality · Assessment of HTLV-1c serology in at-risk populations.
    [Show full text]
  • Drug Resistance in Non-Hodgkin Lymphomas
    International Journal of Molecular Sciences Review Drug Resistance in Non-Hodgkin Lymphomas Pavel Klener 1,2,* and Magdalena Klanova 1,2 1 First Department of Internale Medicine-Hematology, University General Hospital in Prague, 128 08 Prague, Czech Republic; [email protected] 2 Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, 128 53 Prague, Czech Republic * Correspondence: [email protected] or [email protected] Received: 3 February 2020; Accepted: 15 March 2020; Published: 18 March 2020 Abstract: Non-Hodgkin lymphomas (NHL) are lymphoid tumors that arise by a complex process of malignant transformation of mature lymphocytes during various stages of differentiation. The WHO classification of NHL recognizes more than 90 nosological units with peculiar pathophysiology and prognosis. Since the end of the 20th century, our increasing knowledge of the molecular biology of lymphoma subtypes led to the identification of novel druggable targets and subsequent testing and clinical approval of novel anti-lymphoma agents, which translated into significant improvement of patients’ outcome. Despite immense progress, our effort to control or even eradicate malignant lymphoma clones has been frequently hampered by the development of drug resistance with ensuing unmet medical need to cope with relapsed or treatment-refractory disease. A better understanding of the molecular mechanisms that underlie inherent or acquired drug resistance might lead to the design of more effective front-line treatment algorithms based on reliable predictive markers or personalized salvage therapy, tailored to overcome resistant clones, by targeting weak spots of lymphoma cells resistant to previous line(s) of therapy. This review focuses on the history and recent advances in our understanding of molecular mechanisms of resistance to genotoxic and targeted agents used in clinical practice for the therapy of NHL.
    [Show full text]
  • Two Cases with CD-20 Negative Diffuse Large B-Cell Lymphoma and Literature Review
    Open Access Annals of Hematology & Oncology Case Report Two Cases with CD-20 Negative Diffuse Large B-Cell Lymphoma and Literature Review Miranda-Aquino T*, Pérez-Topete SE and Montemayor-Montoya JL Abstract Department of Internal Medicine, Hospital Christus CD 20 negative diffuse large B-cell lymphoma is a very rare and aggressive Muguerza, Mexico neoplasm. We report two subtypes of this neoplasm: anaplastic lymphoma *Corresponding author: Tomas Miranda Aquino, kinase positive diffuse large B-cell lymphoma and a plasmablastic lymphoma. Department of Internal Medicine, Hospital Christus These pathologies are very difficult to diagnose and treat. The first case was Muguerza, UDEM, 1ra Av 758 Jardines de Anáhuac, San anaplastic lymphoma kinase positive diffuse large B-cell lymphoma, the patient Nicolás de los Garza, Nuevo León, México received multiple schemes of chemotherapy with a torpid evolution and the patient died. The second case is a plasmablastic lymphoma, the patient was Received: March 24, 2016; Accepted: May 18, 2016; treated with infusional etoposide, vincristine, doxorubicin, cyclophosphamide Published: May 20, 2016 and prednisone dose-adjusted chemotherapy, the treatment was successful with complete remission and without relapses. Keywords: CD 20 negative diffuses large B-cell lymphoma; Diffuse large B-cell lymphoma ALK positive; Plasmablastic lymphoma; Infusional DA- EPOCH; CHOP-Bleo Abbreviations and with a high proliferation index [2], with poor response to current therapies [3]. We report two cases with this diagnosis.
    [Show full text]
  • Targeted Drugs As Maintenance Therapy After Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma
    pharmaceuticals Review Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma Fengting Yan 1,2, Ajay K. Gopal 1,2 and Solomon A. Graf 1,2,3,* 1 Department of Medicine, University of Washington, Seattle, WA 98195, USA; [email protected] (F.Y.); [email protected] (A.K.G.) 2 Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA 3 Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA * Correspondence: [email protected]; Tel.: +01-206-277-4757 Academic Editor: Luciano J. Costa Received: 27 January 2017; Accepted: 8 March 2017; Published: 10 March 2017 Abstract: The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving toward the incorporation of novel and biologically targeted pharmaceuticals with improved disease activity and gentler toxicity profiles compared with conventional chemotherapeutics. Upfront intensive treatment of MCL includes autologous stem cell transplantation (SCT) consolidation aimed at deepening and lengthening disease remission, but subsequent relapse occurs. Maintenance therapy after autologous SCT in patients with MCL in remission features lower-intensity treatments given over extended periods to improve disease outcomes. Targeted drugs are a natural fit for this space, and are the focus of considerable clinical investigation. This review summarizes recent advances in the field and their potential impact on treatment practices for MCL. Keywords: stem cell transplantation; mantle cell lymphoma; maintenance therapy 1. Introduction Mantle cell lymphoma (MCL) is an uncommon and heterogeneous subtype of B-cell non-Hodgkin lymphoma (B-NHL). It arises from antigen-naïve B-cells that proliferate in the mantle zone of lymph node germinal centers, and typically presents in an advanced stage, involving lymph nodes and extranodal sites including the gastrointestinal tract.
    [Show full text]
  • The Role of Glucocorticoids in the Treatment of Non-Hodgkin Lymphoma
    Open Access Annals of Hematology & Oncology Review Article The Role of Glucocorticoids in the Treatment of Non- Hodgkin Lymphoma Lamar ZS1,2* 1Department of Internal Medicine, Section on Abstract Hematology and Oncology, Wake Forest School of First line chemotherapy for aggressive non-Hodgkin lymphoma (NHL) Medicine, USA typically involves high doses of glucocorticoids (GCs) over several days. The 2Comprehensive Cancer Center, Wake Forest Baptist most commonly used combination chemotherapy regimen for NHL includes Medical Center, Winston Salem, USA cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) or given *Corresponding author: Zanetta S. Lamar, with rituximab (R-CHOP). The dose of prednisone used in the R-CHOP Department of Internal Medicine, Section on Hematology regimen varies in historical studies and in current clinical trials. There is a and Oncology, Wake Forest School of Medicine, Medical paucity of prospective data outlining the management of hyperglycemia during Center Blvd, Winston Salem, NC 27157, USA chemotherapy in diabetics or the risk of hyperglycemia or steroid-induced hyperglycemia during or following chemotherapy. Often, the adverse short and Received: June 18, 2016; Accepted: August 22, 2016; long-term effects of high doses of GCs are not reported in clinical trials. We Published: August 24, 2016 will discuss the history of GC incorporation into combination chemotherapy for lymphoma, the potential implications of liberal GC use in this population, and the opportunities for further research. Keywords: Glucocorticoid; Steroid; Non-Hodgkin lymphoma; Diabetes; Cancer; Hyperglycemia Introduction apoptosis is dependent on adequate levels of the GCR, the mechanism of GC-induced apoptosis is complex and involves multiple signaling Glucocorticoids (GCs) are a class of steroid hormones produced pathways [10,11].
    [Show full text]
  • Modified DHAP Regimen in the Salvage Treatment of Refractory Or
    Journal of Cancer Research and Clinical Oncology (2019) 145:3067–3073 https://doi.org/10.1007/s00432-019-03027-6 ORIGINAL ARTICLE – CLINICAL ONCOLOGY Modifed DHAP regimen in the salvage treatment of refractory or relapsed lymphomas Frank Kroschinsky1 · Denise Röllig1 · Barbara Riemer1 · Michael Kramer1 · Rainer Ordemann1 · Johannes Schetelig1 · Martin Bornhäuser1 · Gerhard Ehninger1 · Mathias Hänel2 Received: 6 June 2019 / Accepted: 16 September 2019 / Published online: 28 September 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Background The combination of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) is an established salvage regi- men for lymphoma patients. We hypothesized that a modifed administration schedule for cisplatin and cytarabine results in lower toxicity and improved efcacy. Methods We retrospectively analysed 119 patients with relapsed or refractory, aggressive, or indolent B-cell lymphomas, mantle-cell lymphomas, peripheral T-cell lymphomas, or Hodgkin’s lymphomas who were treated with the modifed DHAP (mDHAP) regimen (dexamethasone 40 mg 15 min-i.v. infusion, days 1–4; cytarabine 2 × 0.5 g/m2 1 h-i.v. infusion, days 1–4; cisplatin 25 mg/m2 24 h-i.v. infusion, days 1–4). Responding and eligible patients underwent stem-cell transplantation. Results In total, 185 treatment cycles were evaluable. Severe myelosuppression was the main toxicity occurring in 90% of the cycles. Febrile neutropenia or documented infection was found in less than 40%. Two patients died related to treatment (TRM, 1.7%). Nephrotoxicity did not exceed CTC grade 3, which occurred in four cycles only (2.2%). Complete (CR) or partial (PR) responses after mDHAP were documented in 16% and 39% (overall response rate 55%).
    [Show full text]
  • Mechanisms of Resistance to Monoclonal Antibodies (Mabs) in Lymphoid Malignancies
    Current Hematologic Malignancy Reports (2019) 14:426–438 https://doi.org/10.1007/s11899-019-00542-8 B-CELL NHL, T-CELL NHL, AND HODGKIN LYMPHOMA (J AMENGUAL, SECTION EDITOR) Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies Pallawi Torka 1 & Mathew Barth2 & Robert Ferdman1 & Francisco J. Hernandez-Ilizaliturri1,3,4 Published online: 26 September 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival of cancer patients. This review focuses on the available data on mechanisms of resistance to rituximab and includes some additional information for other mAbs currently in use in hematological malignancies. Recent Findings Mechanisms of resistance have been identified that target all described mechanisms of mAb activity including altered antigen expression or binding, impaired complement-mediated cytotoxicity (CMC) or antibody-dependent cellular cy- totoxicity (ADCC), altered intracellular signaling effects, and inhibition of direct induction of cell death. Numerous approaches to circumvent identified mechanisms of resistance continue to be investigated, but a thorough understanding of which resistance mechanisms are most clinically relevant is still elusive. In recent years, a deeper understanding of the tumor microenvironment and targeting the apoptotic pathway has led to promising breakthroughs. Summary Resistance may be driven by unique patient-, disease-, and antibody-related factors. Understanding the mechanisms of resistance to mAbs will guide the development of strategies to overcome resistance and re-sensitize cancer cells to these biological agents.
    [Show full text]
  • Peripheral T-Cell Lymphoma
    NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Peripheral T-Cell Lymphoma (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Systemic Therapy for Peripheral T-Cell Lymphomas1 Note: All recommendations are Category 2A unless otherwise indicated. First-Line Therapy ALCL, ALK+ Histology REGIMEN DOSING CHOP2-5a Day 1: Cyclophosphamide 750mg/m2 IV + doxorubicin 50mg/m2 IV + vincristine 2mg IV Days 1–5: Prednisone 100mg orally. Repeat every 3 weeks for 6 cycles.
    [Show full text]
  • Sequential Chemotherapy by CHOP and DHAP Regimens Followed By
    Leukemia (2002) 16, 587–593 2002 Nature Publishing Group All rights reserved 0887-6924/02 $25.00 www.nature.com/leu Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study F Lefre`re1, A Delmer2, F Suzan3, V Levy4, C Belanger1, M Djabarri5, B Arnulf1, GDamaj 1, N Maillard1, V Ribrag6, M Janvier7, C Sebban8, R-O Casasnovas9, R Bouabdallah10, F Dreyfus5, V Verkarre11, E Delabesse12, F Valensi12, E McIntyre12, N Brousse11, B Varet1 and O Hermine1 1Service d’He´matologie Adultes, Hoˆpital Necker, Paris, France; 2Service des Maladies du Sang Hoˆpital de l’Hotel-Dieu, Paris, France; 3Service d’Onco-He´matologie, Hoˆpital Andre´ Mignot, Versailles, France; 4De´partement de Biostatistique Me´dicale, INSERM U444, Hoˆpital Saint-Louis, Paris, France; 5Service d’He´matologie, Hoˆpital Cochin, Paris, France; 6Institut Gustave Roussy, Villejuif, France; 7Service d’Oncologie, Centre Rene´ Huguenin, St-Cloud, France; 8Service d’He´matologie, Hoˆpital Edouard Herriot, Lyon, France; 9Service d’He´matologie, Centre Hospitalier, Dijon, France; 10Service d’He´matologie, Institut Paoli-Calmette, Marseille, France; 11Service d’Anatomopathologie, Hoˆpital Necker, Paris, France; and 12Laboratoire d’He´matologie, Hoˆpital Necker, Paris, France Mantle cell lymphoma (MCL) is a distinct clinico-pathological levels are observed in more than 50% of patients during the entity with a poor prognosis. We have conducted a prospective progression of the disease. However, although the inter- study in patients with MCL to evaluate a therapeutic strategy in which CHOP polychemotherapy was followed by DHAP if CHOP national prognostic factor index may be applied to MCL failed to induce complete remission.
    [Show full text]
  • Pdf 291.42 K
    DOI:10.22034/APJCP.2018.19.2.331 Cd20 Expression and Effects on Outcome of Relapsed/Refractory Diffuse Large B Cell Lymphoma RESEARCH ARTICLE Editorial Process: Submission:08/29/2016 Acceptance:12/04/2017 Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab Afshan Asghar Rasheed1, Adeel Samad2, Ahmed Raheem1, Samina Ismail Hirani2, Munira Shabbir- Moosajee1* Abstract Introduction: Down regulation of CD20 expression has been reported in diffuse large B cell lymphoma (DLBCL)). Therefore, it is important to determine whether chemotherapy with rituximab induces CD20 down regulation and effects survival. Objectives: To determine the incidence of down regulation of CD20 expression in relapsed DLBCL after treatment with rituximab and to compare outcomes and assess pattern of relapse between CD20 negative and CD20 positive cases. Methodology: We retrospectively reviewed patients with relapsed DLBCL who received rituximab in the first line setting at Aga Khan University Hospital between January 2007 and December 2014. Data were recorded on predesigned questionnaires, with variables including demographics, details regarding date of diagnosis and relapse, histology, staging, international prognostic index, treatment and outcomes at initial diagnosis and at relapse. The Chi square test was applied to determine statistical significance between categorical variables. Survival curves were generated by the Kaplan–Meier method. Results: A total of 54 patients with relapsed DLBCL were included in our study, 38 (70 %) males and 16(30%) females. Some 23 (43%) patients were at stage IV at the time of diagnosis and 34 (63%) had B symptoms. The most frequent R-IPI at diagnosis was II in 24 (44%) patients.
    [Show full text]
  • Ofatumumab, a Second- Generation Anti-CD20 Monoclonal Antibody, For
    Drug Evaluation 1 2 Ofatumumab, a second- 3 4 generation anti-CD20 monoclonal 5 6 antibody, for the treatment 7 1. Introduction 8 of lymphoproliferative and 9 2. Synthesis 10 3. Preclinical development autoimmune disorders 11 4. Clinical development † 12 Jorge Castillo , Cannon Milani & Daniel Mendez-Allwood 5. Adverse events and † 13 Brown University Warren Alpert Medical School, The Miriam Hospital, Division of Hematology and contraindications 14 Oncology, Providence, RI, USA 15 6. Conclusions Background: Lymphoproliferative and autoimmune disorders share monoclonal 16 7. Expert opinion dysregulation and survival advantage of B-lymphocytes. Thus, therapies 17 18 directed towards eliminating B-cells will play an important role as CD20 is 19 exclusively expressed in B-lymphocytes and its modulation by monoclonal 20 antibodies such as rituximab has improved outcomes in lymphoproliferative 21 and autoimmune disorders. Ofatumumab is a new, fully human anti-CD20 22 antibody and has been shown to be effective and safe, but its role in these 23 conditions is still unclear. Objectives: To describe the preclinical and clinical 24 data available on ofatumumab for the treatment of lymphoproliferative 25 and autoimmune disorders. Methods: An extensive search of published 26 articles and abstracts on preclinical and clinical studies with ofatumumab 27 was undertaken. Conclusions: Ofatumumab is a second-generation anti- 28 CD20 antibody that has been demonstrated to be safe and efficacious in 29 patients with lymphoproliferative and autoimmune disorders. Ofatumumab 30 is fully human, attaches to a newly identified epitope and shows lower off- 31 rates and improved complement-dependent cytotoxicity. Initial data present 32 ofatumumab as an attractive agent with lower rates of infusion-related 33 events than rituximab.
    [Show full text]